VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $160,345,304 | +1.5% | 3,145,259 | -0.6% | 0.01% | +12.5% |
| Q2 2023 | $157,975,801 | +37.0% | 3,163,312 | +2.8% | 0.01% | +14.3% |
| Q1 2023 | $115,289,080 | -62.1% | 3,076,016 | -51.5% | 0.01% | -22.2% |
| Q4 2022 | $303,809,378 | +535.1% | 6,335,962 | +217.9% | 0.01% | +200.0% |
| Q3 2022 | $47,833,000 | +18.5% | 1,993,036 | +7.4% | 0.00% | +50.0% |
| Q2 2022 | $40,379,000 | +20.8% | 1,855,644 | +34.1% | 0.00% | 0.0% |
| Q1 2022 | $33,428,000 | +19.6% | 1,384,168 | +17.8% | 0.00% | +100.0% |
| Q4 2021 | $27,952,000 | -3.0% | 1,174,931 | +3.4% | 0.00% | -50.0% |
| Q3 2021 | $28,827,000 | -14.8% | 1,136,254 | -24.4% | 0.00% | 0.0% |
| Q2 2021 | $33,838,000 | -3.3% | 1,503,263 | -15.2% | 0.00% | 0.0% |
| Q1 2021 | $34,999,000 | +42.9% | 1,772,076 | +92.2% | 0.00% | +100.0% |
| Q4 2020 | $24,493,000 | +81.0% | 921,830 | +236.4% | 0.00% | 0.0% |
| Q3 2020 | $13,532,000 | – | 274,041 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $82,124,000 | 28.36% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $37,277,000 | 21.71% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,405,421 | $27,757,000 | 8.90% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $45,614,000 | 3.66% |
| RA Capital Management | 3,865,808 | $76,350,000 | 1.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,558,475 | $90,030,000 | 1.05% |
| Soleus Capital Management, L.P. | 293,650 | $5,800,000 | 1.04% |
| Opaleye Management Inc. | 357,800 | $7,067,000 | 1.04% |
| SABBY MANAGEMENT, LLC | 178,992 | $3,535,000 | 0.69% |
| Penn Mutual Asset Management, LLC | 22,227 | $439,000 | 0.50% |